Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated August 04, 2025, titled "Press release on financial results for the quarter ended June 30, 2025".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
OneSource Specialty Pharma reported Q1FY26 consolidated revenue of ₹3,273 million, up 12% YoY from ₹2,923 million, driven by execution of master service agreements. EBITDA rose 37% YoY to ₹885 million, with margin expanding ~500 basis points to 27%. Adjusted PAT turned around from a loss of ₹77 million in Q1FY25 to a profit of ₹371 million, translating to adjusted EPS of ₹3.2. The company secured 6 new contracts and received 25 RFPs during the quarter, and its flagship DDC facility cleared back-to-back USFDA and ANVISA Brazil inspections. Separately, the board formed a sub-committee of independent directors to evaluate a potential acquisition of two USFDA-approved manufacturing assets from Steriscience — a fill-finish facility in Warsaw, Poland and a carbapenem facility in Vadodara, India. FY28 organic targets of >30% revenue CAGR and ~40% EBITDA margins were reaffirmed.
Strong quarter with broad-based growth and a sharp swing from loss to profit is likely to be viewed positively by the market. The proposed Steriscience acquisition, if completed, could significantly expand manufacturing capacity and product offerings, but remains subject to detailed evaluation and regulatory and shareholder approvals.